Literature DB >> 12149204

De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.

Thierry Dervieux1, Timothy L Brenner, Yuen Y Hon, Yinmei Zhou, Michael L Hancock, John T Sandlund, Gaston K Rivera, Raul C Ribeiro, James M Boyett, Ching-Hon Pui, Mary V Relling, William E Evans.   

Abstract

Methotrexate (MTX) and mercaptopurine (MP) are widely used antileukemic agents that inhibit de novo purine synthesis (DNPS) as a mechanism of their antileukemic effects. To elucidate pharmacodynamic differences among children with acute lymphoblastic leukemia (ALL), DNPS was measured in leukemic blasts from newly diagnosed patients before and after therapy with these agents. Patients were randomized to receive low-dose MTX (LDMTX: 6 oral doses of 30 mg/m(2)) or high-dose MTX (HDMTX: intravenous 1 g/m(2)) followed by intravenous MP; or intravenous MP alone (1 g/m(2)), as initial therapy. At diagnosis, the rate of DNPS in bone marrow leukemia cells was 3-fold higher in patients with T-lineage ALL compared with those with B-lineage ALL (769 +/- 189 vs 250 +/- 38 fmol/nmol/h; P =.001). DNPS was not consistently inhibited following MP alone but was markedly inhibited following MTX plus MP (median decrease 3% vs 94%; P <.001). LDMTX plus MP and HDMTX plus MP produced greater antileukemic effects (percentage decrease in circulating leukocyte counts) compared with MP alone (-50% +/- 4%, -56% +/- 3%, and - 20% +/- 4%, respectively; P <.0001). Full DNPS inhibition was associated with greater antileukemic effects compared with partial or no inhibition (-63% +/- 4% vs -37% +/- 4%; P <.0001) in patients with nonhyperdiploid B-lineage and T-lineage ALL. HDMTX plus MP yielded 2-fold higher MTX polyglutamate concentrations than LDMTX plus MP (2148 +/- 298 vs 1075 +/- 114 pmol/10(9) cells; P <.01) and a higher percentage of patients with full DNPS inhibition (78% vs 53%; P <.001). Thus, the extent of DNPS inhibition was related to in vivo antileukemic effects, and a single dose of intravenous MP produced minimal DNPS inhibition and antileukemic effects, whereas MTX plus MP produced greater antileukemic effects and DNPS inhibition, with full inhibition more frequent after HDMTX.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12149204     DOI: 10.1182/blood-2002-02-0495

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.

Authors:  Torben S Mikkelsen; Alex Sparreboom; Cheng Cheng; Yinmei Zhou; James M Boyett; Susana C Raimondi; John C Panetta; W Paul Bowman; John T Sandlund; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

2.  Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.

Authors:  Gianluigi Zaza; Meyling Cheok; Wenjian Yang; John C Panetta; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  Blood       Date:  2005-05-19       Impact factor: 22.113

3.  New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer via small molecule potentiators.

Authors:  Chamitha Weeramange; Ashabha Lansakara; Johnathan Dallman; Thi Nguyen; Wasundara Hulangamuwa; Ryan J Rafferty
Journal:  Medchemcomm       Date:  2019-03-18       Impact factor: 3.597

4.  Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.

Authors:  Leo Kager; Meyling Cheok; Wenjian Yang; Gianluigi Zaza; Qing Cheng; John C Panetta; Ching-Hon Pui; James R Downing; Mary V Relling; William E Evans
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

5.  Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.

Authors:  John C Panetta; Alex Sparreboom; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  PLoS Comput Biol       Date:  2010-12-02       Impact factor: 4.475

6.  Mathematical modeling of folate metabolism.

Authors:  John C Panetta; Steven W Paugh; William E Evans
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2013-05-22

7.  Independent validation of a model using cell line chemosensitivity to predict response to therapy.

Authors:  Wenting Wang; Keith A Baggerly; Steen Knudsen; Jon Askaa; Wiktor Mazin; Kevin R Coombes
Journal:  J Natl Cancer Inst       Date:  2013-08-20       Impact factor: 13.506

8.  Implementation of TPMT testing.

Authors:  Lynne Lennard
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

9.  Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.

Authors:  G Stocco; M H Cheok; K R Crews; T Dervieux; D French; D Pei; W Yang; C Cheng; C-H Pui; M V Relling; W E Evans
Journal:  Clin Pharmacol Ther       Date:  2008-08-06       Impact factor: 6.875

10.  Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.

Authors:  U Hindorf; M Lindqvist; C Peterson; P Söderkvist; M Ström; H Hjortswang; A Pousette; S Almer
Journal:  Gut       Date:  2006-03-16       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.